glp-1 cardiovascular outcome trials Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes Generalizability of Glucagon-Like Peptide-1 Receptor

Erratum in: Nat Commun

10.1210/en.2006-1608 320

For example, if a patient has recurrence of a previously resolved medical condition or if they gain more than 5% weight above their goal weight, then they are likely to continue to gain weight, says Lofton

Constipation: The opposite problem affects another subset of patients

Should symptoms persist despite these measures, short-term symptomatic pharmacotherapy targeting the specific gastrointestinal disturbance may be warranted [78]

It remains to be determined how GLP-1s and their discontinuation impact body composition, including bone density, among women during perimenopause and beyond